Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial
Cramer, Paula, v. Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Fürstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J., Vehling-Kaiser, Ursula, Dürig, Jan, TausJournal:
Haematologica
DOI:
10.3324/haematol.2019.223693
Date:
February, 2020
File:
PDF, 1.37 MB
2020
File converter
More search results
More benefits 
